Rapid molecular infectious disease testing for Group A Streptococcus
Customize your policy alerts
Sign up for select_health Policy CCP.1563 alerts
Get alerted when Policy CCP.1563 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage determinations for rapid molecular (nucleic acid amplification and amplified probe) testing for Group A Streptococcus in members with suspected streptococcal pharyngitis and describes the plan's medical necessity stance for payers and providers.
No material clinical or coverage changes in this revision.
Coverage Determination for Rapid Molecular Testing (Group A Streptococcus)
Primary coverage determination
Covered when ALL of the following are met
Policy conclusion: tests considered investigational for this indication.
Rapid molecular nucleic acid tests for Group A Streptococcus are excluded from medical necessity coverage for members with suspected streptococcal pharyngitis because the policy considers these assays investigational and not clinically proven.
Molecular rapid testing for Group A Streptococcus (including nucleic acid amplification and amplified probe techniques) is designated not medically necessary — investigational for members with suspected streptococcal pharyngitis and is therefore not supported for routine use.
Relevant Procedure and Test Codes
| 87650 | Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group A, direct probe technique. |
| 87651 | Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group A, amplified probe technique. |
| 87652 | Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group A, quantification. |
| 87880 | Infectious agent antigen detection by immunoassay with direct optical observation; Streptococcus, group A. |
| 87081 | Culture, presumptive, pathogenic organisms, screening only. |
Provider Requirements, Workflow, and Denial Risk
Prior authorization: investigational / not medically necessary
Rapid molecular nucleic acid tests for Group A Streptococcus are classified as investigational and not medically necessary; authorization is not supported by this policy for routine use in suspected streptococcal pharyngitis.
Preferred testing workflow: clinical scoring → RADT → culture as indicated
Follow standard, selective diagnostic pathways: use clinical scoring to identify who needs testing, perform rapid antigen detection testing (RADT) as the routine point‑of‑care test, and obtain throat culture confirmation in symptomatic children older than 3 years after a negative RADT when indicated.
- Do not use unselected molecular testing for all patients with sore throat; use risk‑stratified testing guided by clinical scores.
- RADT provides visit‑time results; culture identifies viable organisms but requires incubation.
Documentation & coding: include CPT code and clinical rationale
When submitting claims for molecular Group A Streptococcus testing, include the applicable procedure codes and supporting clinical documentation (signs/symptoms and test rationale).
Denial risk: investigational testing may be denied as not medically necessary
Claims for rapid molecular testing for Group A Streptococcus may be denied as not medically necessary because the policy designates these tests investigational/not clinically proven for suspected streptococcal pharyngitis.
- Denial risk applies when molecular testing is performed for routine evaluation of suspected streptococcal pharyngitis.
- Regulatory clearance or a CPT code does not change the policy’s medical necessity determination.
Clinical Background
Group A Streptococcus (Streptococcus pyogenes) is a common bacterial cause of acute pharyngitis. Rapid molecular tests detect organism-specific nucleic acid from throat swab specimens; while these assays can have high analytic sensitivity and faster turnaround than culture, this policy considers their use investigational for suspected streptococcal pharyngitis and does not deem them medically necessary for routine diagnosis.
Key Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.